Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18177977 | 0.90 | ALDH1A1 (0.41) | ACHETSHRHCAR2L3MBTL1ZDHHC20 | |
| SCHEMBL18177979 | 0.85 | ACHE (0.39) | ACHETSHRALDH1A1NPC1LMNA | |
| SCHEMBL18177951 | 0.83 | NPC1 (0.38) | ACHETSHRNPC1CA12CA1 | |
| SCHEMBL18177955 | 0.82 | ACHE (0.37) | ACHETSHRL3MBTL1ZDHHC20NPC1 | |
| SCHEMBL18177956 | 0.82 | ACHE (0.37) | ACHETSHRALDH1A1LMNACA12 | |
| SCHEMBL2239225 | 0.81 | ALDH1A1 (0.38) | TSHRHCAR2ALDH1A1LMNACA12 | |
| SCHEMBL2238367 | 0.79 | CA12 (0.47) | TSHRHCAR2ALDH1A1LMNACA12 | |
| SCHEMBL18182121 | 0.78 | CA12 (0.39) | ACHETSHRL3MBTL1ZDHHC20NPC1 | |
| SCHEMBL18177957 | 0.77 | ACHE (0.44) | ACHETSHR | |
| SCHEMBL2242976 | 0.76 | CYP3A4 (0.50) | TSHRHCAR2ALDH1A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160315351-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, ELECTRICITY STORAGE DEVICE USING SAME, AND PHOSPHONOFORMIC ACID COMPOUND USED IN SAME | UBE INDUSTRIES, LTD (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20160315351-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, ELECTRICITY STORAGE DEVICE USING SAME, AND PHOSPHONOFORMIC ACID COMPOUND USED IN SAME | UBE INDUSTRIES, LTD (JP) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160315351-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, ELECTRICITY STORAGE DEVICE USING SAME, AND PHOSPHONOFORMIC ACID COMPOUND USED IN SAME | HCN2, PHOSPHO1, HCN1 | ACHE 3134/4885TSHR 3275/4885HCAR2 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.